Approval · Notice of Compliance 33672 · 2024
NAPROXEN: Notice of Compliance 33672
Issued July 19, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33672
- Date
- July 19, 2024
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph to be in line with CRP
- Canadian reference product
- ALEVE CAPLETS (Bayer Inc., Consumer Care Division)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAPROXEN | Not yet assigned | — |
Medicinal ingredients
- NAPROXEN SODIUM 220 MG per TAB